Edwards Lifesciences Earnings Reports

Edwards Lifesciences reported strong Q4 FY24 results with revenue of $1.39 billion, a 9% increase year-over-year. EPS was $0.58, and adjusted EPS was $0.59. Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.04 billion, up 6%, while Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a substantial 88% growth to $105 million. Surgical Structural Heart sales were $244 million, increasing 6%. The company remains confident in its strategic growth areas, with continued expansion in structural heart therapies.

Edwards Lifesciences reported a 9% increase in sales from continuing operations, with constant currency sales growth of 10%. TAVR sales grew by 6%, while TMTT sales saw a significant increase of 73%. The company completed the sale of its Critical Care business and reiterated its full-year sales guidance.

Edwards Lifesciences reported a 7% sales growth in Q2, driven by a strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT) with 75% growth, which was offset by lower-than-expected growth in Transcatheter Aortic Valve Replacement (TAVR). The adjusted EPS was $0.70. The company expects full-year 2024 sales growth of 8 to 10%.

Edwards Lifesciences reported strong first-quarter results, with sales growing 10% to $1.6 billion and adjusted EPS of $0.66. The company has raised its full-year 2024 sales guidance due to this encouraging start of the year.

Edwards Lifesciences reported a strong Q4 2023, with sales up 14% to $1.53 billion and adjusted EPS of $0.64. The company is confident in its 2024 guidance, projecting 8 to 10 percent constant currency sales growth.

Edwards Lifesciences reported a 12% increase in sales to $1.48 billion in Q3 2023. The company's TAVR sales grew by 11%, and it received several regulatory approvals for its innovative therapies. The company reiterated its full-year 2023 financial guidance of 10 to 13 percent constant currency sales growth.

Edwards Lifesciences reported an 11% increase in sales to $1.53 billion in Q2 2023, with all product groups achieving double-digit constant currency sales growth. Adjusted EPS was $0.66. The company has increased its full-year outlook due to strong first-half performance and improved healthcare staffing.

Edwards Lifesciences reported a strong start to 2023, exceeding expectations with Q1 sales growing 9% to $1.46 billion and adjusted EPS of $0.62. The company raised its full-year sales guidance and expects a return to higher sales growth, driven by its patient-focused innovation strategy.

Edwards Lifesciences reported Q4 2022 results, with sales growing 1% to $1.35 billion and adjusted EPS increasing 25% to $0.64. The company highlighted progress on strategic milestones and reiterated its 2023 guidance.

Edwards Lifesciences reported Q3 sales of $1.32 billion, a 1% increase, or 7% on a constant currency basis. Adjusted EPS increased by 13% to $0.61. The company received U.S. FDA and CE Mark approval for PASCAL Precision and U.S. FDA approval for the SAPIEN 3 Ultra RESILIA valve.

Edwards Lifesciences reported flat sales of $1.37 billion in the second quarter of 2022, but underlying sales grew by 5%. EPS was $0.65, and adjusted EPS was $0.63. The company lowered its second-half underlying sales growth outlook to approximately 10% but expects strong double-digit adjusted EPS growth in the second half.

Edwards Lifesciences reported a 10% increase in sales to $1.34 billion in the first quarter, with underlying sales up 13%. The company reaffirmed its full-year financial guidance and saw growth across all regions and product lines.

Edwards Lifesciences reported a 12% increase in Q4 sales to $1.33 billion, with underlying growth of 13%. Adjusted EPS was $0.51. The company reaffirmed its full-year 2022 sales guidance and adjusted EPS expectations.

Edwards Lifesciences reported a 15% increase in sales to $1.3 billion for the third quarter of 2021. The company's TAVR sales grew by 15%, and it made progress on five pivotal trials in TMTT. The company maintained its full-year 2021 sales guidance range and EPS guidance.

Edwards Lifesciences reported a strong second quarter with sales up 49% to $1.4 billion and underlying sales growth of 44%. TAVR sales exceeded expectations, growing 52%. The company raised its full-year sales guidance to $5.2 to $5.4 billion and adjusted EPS guidance to the high end of the previous $2.07 to $2.27 range.

Edwards Lifesciences reported sales of $1.2 billion, an 8% increase over the prior year, with underlying sales growing by 5%. EPS reached $0.54, surpassing expectations. The company is confident in its 2021 outlook and raised its adjusted EPS guidance.

Edwards Lifesciences reported Q4 sales increased 1 percent to $1.2 billion, with underlying sales flat. The company's Q4 EPS was $0.49, and adjusted EPS grew 2 percent to $0.50. The company reiterated its 2021 guidance with sales growth expected in the mid-teens.

Edwards Lifesciences reported a 4% increase in sales to $1.1 billion for the third quarter of 2020. Diluted earnings per share were $0.52, and adjusted earnings per share grew 9% to $0.51. The company is raising the bottom end of full-year 2020 adjusted earnings per share guidance to $1.85 to $1.95.

Edwards Lifesciences reported a 15% decrease in sales to $925 million, with TAVR sales declining by 12%. EPS was negative $0.20, while adjusted EPS decreased 26% to $0.34. The company reiterated its 2020 sales guidance of $4.0 billion to $4.5 billion and increased its adjusted EPS guidance to $1.75 to $1.95.

Edwards Lifesciences reported a 14% increase in sales to $1.1 billion for the first quarter of 2020. Diluted EPS was $1.47, and adjusted EPS grew 14% to $1.51. The company's sales were significantly impacted by COVID-19 in the last few weeks of the quarter, leading to a substantial reduction in 2020 sales and EPS guidance.

Edwards Lifesciences reported a strong fourth quarter with sales growth of 20% to $1.2 billion and adjusted EPS growth of 25% to $1.46. The company's full year sales and earnings significantly exceeded original guidance. 2020 guidance ranges increased: sales $4.6 billion to $5.0 billion; EPS $6.15 to $6.40